{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T19:55:42Z","timestamp":1783540542045,"version":"3.55.0"},"reference-count":111,"publisher":"Journal of Neurosurgery Publishing Group (JNSPG)","issue":"Suppl","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JNS"],"published-print":{"date-parts":[[2014,8]]},"abstract":"<jats:p>Patients receiving anticoagulation therapy who present with any type of intracranial hemorrhage\u2014including subdural hematoma, epidural hematoma, subarachnoid hemorrhage, and intracerebral hemorrhage (ICH)\u2014require urgent correction of their coagulopathy to prevent hemorrhage expansion, limit tissue damage, and facilitate surgical intervention as necessary. The focus of this review is acute ICH, but the principles of management for anticoagulation-associated ICH (AAICH) apply to patients with all types of intracranial hemorrhage, whether acute or chronic.<\/jats:p>\n<jats:p>A number of therapies\u2014including fresh frozen plasma (FFP), intravenous vitamin K, activated and inactivated prothrombin complex concentrates (PCCs), and recombinant activated factor VII (rFVIIa)\u2014have been used alone or in combination to treat AAICH to reverse anticoagulation, help achieve hemodynamic stability, limit hematoma expansion, and prepare the patient for possible surgical intervention. However, there is a paucity of high-quality data to direct such therapy. The use of 3-factor PCC (activated and inactivated) and rFVIIa to treat AAICH constitutes off-label use of these therapies in the United States. However, in April 2013, the US Food and Drug Administration (FDA) approved Kcentra (a 4-factor PCC) for the urgent reversal of vitamin K antagonist (VKA) anticoagulation in adults with acute major bleeding. Plasma is the only other product approved for this use in the United States.<jats:sup>1<\/jats:sup> Inconsistent recommendations, significant barriers (e.g., clinician-, therapy-, or logistics-based barriers), and a lack of approved treatment pathways in some institutions can be potential impediments to timely and evidence-based management of AAICH with available therapies. Patient assessment, therapy selection, whether to use a reversal or factor repletion agent alone or in combination with other agents, determination of site-of-care management, eligibility for neurosurgery, and potential hematoma evacuation are the responsibilities of the neurosurgeon, but ultimate success requires a multidisciplinary approach with consultation from the emergency department (ED) physician, pharmacist, hematologist, intensivist, neurologist, and, in some cases, the trauma surgeon.<\/jats:p>","DOI":"10.3171\/2014.8.paradigm","type":"journal-article","created":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T10:59:45Z","timestamp":1542365985000},"page":"1-20","source":"Crossref","is-referenced-by-count":40,"title":["Race against the clock: Overcoming challenges in the management of anticoagulant-associated intracerebral hemorrhage"],"prefix":"10.3171","volume":"121","author":[{"given":"Peter","family":"Le Roux","sequence":"first","affiliation":[{"name":"Thomas Jefferson University, Philadelphia, Pennsylvania and Brain and Spine Center, Lankenau Medical Center, Wynnewood, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles V.","family":"Pollack","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Perelman School of Medicine, University of Pennsylvania and Department of Emergency Medicine, Pennsylvania Hospital, Philadelphia, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Milan","sequence":"additional","affiliation":[{"name":"Paradigm Medical Communications, LLC, Orangeburg, New York; and"},{"name":"Union Memorial Hospital, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisa","family":"Schaefer","sequence":"additional","affiliation":[{"name":"Paradigm Medical Communications, LLC, Orangeburg, New York; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1754","reference":[{"key":"b1-augsuppjns2014","article-title":"FDA approves Kcentra for the urgent reversal of anticoagulation in adults with major bleeding","author":"US Food and Drug Administration","year":"2013"},{"key":"b2-augsuppjns2014","series-title":"Brain","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1093\/brain\/aws349","article-title":"Intracerebral haemorrhage profiles are changing: results from the Dijon population-based study","volume":"136","author":"Bejot","year":"2013"},{"key":"b3-augsuppjns2014","series-title":"J Stroke Cerebrovasc Dis","article-title":"Incidence and Cost of Stroke and Hemorrhage in Patients Diagnosed with Atrial Fibrillation in France","author":"Cotte","year":"2013"},{"key":"b4-augsuppjns2014","series-title":"Stroke","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1161\/STROKEAHA.111.000529","article-title":"Risk factors for intracerebral hemorrhage: the REasons for geographic and racial differences in stroke (REGARDS) study","volume":"44","author":"Howard","year":"2013"},{"key":"b5-augsuppjns2014","series-title":"Lancet Neurol","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S1474-4422(09)70340-0","article-title":"Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis","volume":"9","author":"van Asch","year":"2010"},{"issue":"1","key":"b6-augsuppjns2014","series-title":"Int J Emerg Med","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1865-1380-4-40","article-title":"Treatments for reversing warfarin anticoagulation in patients with acute intracranial hemorrhage: a structured literature review","volume":"4","author":"Bechtel","year":"2011"},{"key":"b7-augsuppjns2014","series-title":"Stroke","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1161\/STROKEAHA.108.538462","article-title":"The challenge of designing a treatment trial for warfarin-associated intracerebral hemorrhage","volume":"40","author":"Flaherty","year":"2009"},{"key":"b8-augsuppjns2014","series-title":"Stroke","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1161\/STROKEAHA.108.520668","article-title":"Hematoma growth in oral anticoagulant related intracerebral hemorrhage","volume":"39","author":"Cucchiara","year":"2008"},{"key":"b9-augsuppjns2014","series-title":"Stroke","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1161\/STROKEAHA.112.652065","article-title":"Poor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal","volume":"43","author":"Dowlatshahi","year":"2012"},{"key":"b10-augsuppjns2014","series-title":"Lancet Neurol","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S1474-4422(07)70107-2","article-title":"Change in incidence and aetiology of intracerebral haemorrhage in Oxfordshire, UK, between 1981 and 2006: a population-based study","volume":"6","author":"Lovelock","year":"2007"},{"key":"b11-augsuppjns2014","series-title":"J Neurol","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s00415-011-6153-3","article-title":"Oral anticoagulant-associated intracerebral hemorrhage","volume":"259","author":"Cervera","year":"2012"},{"key":"b12-augsuppjns2014","series-title":"Europace","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1093\/europace\/eus305","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation\u2014developed with the special contribution of the European Heart Rhythm Association","volume":"14","author":"Camm","year":"2012"},{"key":"b13-augsuppjns2014","series-title":"Chest","doi-asserted-by":"publisher","first-page":"160S","DOI":"10.1378\/chest.08-0670","article-title":"Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Ansell","year":"2008"},{"issue":"11","key":"b14-augsuppjns2014","series-title":"World J Cardiol","doi-asserted-by":"publisher","first-page":"351","DOI":"10.4330\/wjc.v3.i11.351","article-title":"Incidence, clinical impact and risk of bleeding during oral anticoagulation therapy","volume":"3","author":"Rubboli","year":"2011"},{"key":"b15-augsuppjns2014","series-title":"Med Decis Making","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1177\/0272989X09343960","article-title":"Patient time requirements for anticoagulation therapy with warfarin","volume":"30","author":"Jonas","year":"2010"},{"key":"b16-augsuppjns2014","series-title":"Mayo Clin Proc","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S0025-6196(11)60970-1","article-title":"Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion","volume":"82","author":"Aguilar","year":"2007"},{"key":"b17-augsuppjns2014","series-title":"Europace","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1093\/europace\/euq350","article-title":"Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)","volume":"12","author":"Camm","year":"2010"},{"key":"b18-augsuppjns2014","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty","volume":"358","author":"Eriksson","year":"2008"},{"key":"b19-augsuppjns2014","series-title":"Vasc Health Risk Manag","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.2147\/VHRM.S3266","article-title":"Emergence of new oral antithrombotics: a critical appraisal of their clinical potential","volume":"4","author":"Lassen","year":"2008"},{"key":"b20-augsuppjns2014","series-title":"Chest","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1378\/chest.129.5.1155","article-title":"Effect of study setting on anticoagulation control: a systematic review and metaregression","volume":"129","author":"van Walraven","year":"2006"},{"key":"b21-augsuppjns2014","series-title":"Pradaxa\u00ae (dabigatran etexilate mesylate). Package insert"},{"key":"b22-augsuppjns2014","series-title":"Xarelto\u00ae (rivaroxaban). Package insert"},{"key":"b23-augsuppjns2014","series-title":"Eliquis\u00ae (apixaban). Package insert"},{"issue":"13","key":"b24-augsuppjns2014","series-title":"Am J Health Syst Pharm","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.2146\/ajhp110418","article-title":"Apixaban: a novel oral inhibitor of factor Xa","volume":"69","author":"Nutescu","year":"2012"},{"issue":"2 Suppl","key":"b25-augsuppjns2014","series-title":"Chest","doi-asserted-by":"publisher","first-page":"e44S","DOI":"10.1378\/chest.11-2292","article-title":"Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Ageno","year":"2012"},{"key":"b26-augsuppjns2014","series-title":"Chest","doi-asserted-by":"publisher","first-page":"108S","DOI":"10.1378\/chest.119.1_suppl.108S","article-title":"Hemorrhagic complications of anticoagulant treatment","volume":"119","author":"Levine","year":"2001"},{"key":"b27-augsuppjns2014","series-title":"Pharmacotherapy","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1592\/phco.31.12.1175","article-title":"Novel oral anticoagulants and their role in clinical practice","volume":"31","author":"Wittkowsky","year":"2011"},{"key":"b28-augsuppjns2014","series-title":"Clin Pharmacokinet","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/0003088-200948010-00001","article-title":"Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development","volume":"48","author":"Eriksson","year":"2009"},{"key":"b29-augsuppjns2014","series-title":"Neurosurg Focus","doi-asserted-by":"publisher","first-page":"E7","DOI":"10.3171\/2013.2.FOCUS1323","article-title":"Dabigatran, intracranial hemorrhage, and the neurosurgeon","volume":"34","author":"Awad","year":"2013"},{"key":"b30-augsuppjns2014","series-title":"Cardiovasc Ther","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/j.1755-5922.2010.00209.x","article-title":"New antithrombotics for atrial fibrillation","volume":"28","author":"Bereznicki","year":"2010"},{"key":"b31-augsuppjns2014","series-title":"Cleve Clin J Med","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3949\/ccjm.80a.13025","article-title":"Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban","volume":"80","author":"Fawole","year":"2013"},{"key":"b32-augsuppjns2014","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009"},{"key":"b33-augsuppjns2014","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011"},{"key":"b34-augsuppjns2014","series-title":"N Engl J Med.","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011"},{"key":"b35-augsuppjns2014","series-title":"J Clin Neurosci","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/j.jocn.2013.05.009","article-title":"New-generation oral anticoagulants for the prevention of stroke: Implications for neurosurgery","volume":"20","author":"El Ahmadieh","year":"2013"},{"key":"b36-augsuppjns2014","series-title":"Neurology","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1212\/01.WNL.0000138428.40673.83","article-title":"Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage","volume":"63","author":"Flibotte","year":"2004"},{"key":"b37-augsuppjns2014","series-title":"Arch Intern Med.","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1001\/archinte.164.8.880","article-title":"The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage","volume":"164","author":"Rosand","year":"2004"},{"key":"b38-augsuppjns2014","series-title":"Int J Stroke","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/j.1747-4949.2011.00595.x","article-title":"The practical management of intracerebral hemorrhage associated with oral anticoagulant therapy","volume":"6","author":"Masotti","year":"2011"},{"key":"b39-augsuppjns2014","series-title":"Stroke","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1161\/STROKEAHA.111.636720","article-title":"Hemostatic therapy should be used for acute treatment of anticoagulation-related intracerebral hemorrhage","volume":"43","author":"Diringer","year":"2012"},{"key":"b40-augsuppjns2014","series-title":"Thromb Haemost","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1160\/TH11-01-0052","article-title":"Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis","volume":"106","author":"Dentali","year":"2011"},{"key":"b41-augsuppjns2014","series-title":"Stroke","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1161\/STROKEAHA.112.661454","article-title":"Clinical experience with three-factor prothrombin complex concentrate to reverse warfarin anticoagulation in intracranial hemorrhage","volume":"43","author":"Switzer","year":"2012"},{"key":"b42-augsuppjns2014","series-title":"Thromb Res","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.thromres.2012.10.001","article-title":"Systematic review: 3-factor versus 4-factor prothrombin complex concentrate for warfarin reversal: does it matter?","volume":"130","author":"Voils","year":"2012"},{"key":"b43-augsuppjns2014","series-title":"Crit Care","doi-asserted-by":"publisher","first-page":"R4","DOI":"10.1186\/cc11923","article-title":"A French multicenter randomised trial comparing two dose-regimens of prothrombin complex concentrates in urgent anticoagulation reversal","volume":"17","author":"Kerebel","year":"2013"},{"key":"b44-augsuppjns2014","series-title":"Circulation","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1161\/CIRCULATIONAHA.113.002283","article-title":"Efficacy and Safety of a 4-Factor Prothrombin Complex Concentrate in Patients on Vitamin K Antagonists Presenting With Major Bleeding: A Randomized, Plasma-Controlled, Phase IIIb Study","volume":"128","author":"Sarode"},{"key":"b45-augsuppjns2014","series-title":"Circulation","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1161\/CIRCULATIONAHA.113.001875","article-title":"Outcomes of urgent warfarin reversal with frozen plasma versus prothrombin complex concentrate in the emergency department","volume":"128","author":"Hickey","year":"2013"},{"key":"b46-augsuppjns2014","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1056\/NEJMoa0707534","article-title":"Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage","volume":"358","author":"Mayer","year":"2008"},{"key":"b47-augsuppjns2014","series-title":"Stroke","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1161\/STROKEAHA.109.561712","article-title":"Thromboembolic events with recombinant activated factor VII in spontaneous intracerebral hemorrhage: results from the Factor Seven for Acute Hemorrhagic Stroke (FAST) trial","volume":"41","author":"Diringer","year":"2010"},{"key":"b48-augsuppjns2014","series-title":"Stroke","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1161\/STROKEAHA.110.581538","article-title":"Safety of recombinant activated factor VII in patients with warfarin-associated hemorrhages of the central nervous system","volume":"41","author":"Robinson","year":"2010"},{"key":"b49-augsuppjns2014","series-title":"Thromb Res","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.thromres.2006.05.011","article-title":"Prothrombin complex concentrate versus recombinant factor VIIa for reversal of coumarin anticoagulation","volume":"119","author":"Dickneite","year":"2007"},{"key":"b50-augsuppjns2014","series-title":"Stroke","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1161\/STROKEAHA.111.648840","article-title":"The role of hemostatic therapy in anticoagulation-associated intracerebral hemorrhage: intuition versus evidence","volume":"43","author":"Selim","year":"2012"},{"key":"b51-augsuppjns2014","series-title":"Lancet Neurol","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/S1474-4422(13)70049-8","article-title":"Intracerebral haemorrhage associated with antithrombotic treatment: translational insights from experimental studies","volume":"12","author":"Lauer","year":"2013"},{"key":"b52-augsuppjns2014","series-title":"Am J Kidney Dis","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1053\/j.ajkd.2012.08.047","article-title":"Removal of dabigatran by hemodialysis","volume":"61","author":"Chang","year":"2013"},{"key":"b53-augsuppjns2014","series-title":"Circulation","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.111.029017","article-title":"Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects","volume":"124","author":"Eerenberg","year":"2011"},{"key":"b54-augsuppjns2014","series-title":"Stroke","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1161\/STROKEAHA.111.624650","article-title":"Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran","volume":"42","author":"Zhou","year":"2011"},{"key":"b55-augsuppjns2014","series-title":"Clin Res Cardiol","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00392-013-0560-7","article-title":"Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban","volume":"102","author":"Steiner","year":"2013"},{"issue":"4","key":"b56-augsuppjns2014","series-title":"Int J Cardiol","doi-asserted-by":"publisher","first-page":"4228","DOI":"10.1016\/j.ijcard.2013.07.152","article-title":"Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis","volume":"168","author":"Martin","year":"2013"},{"key":"b57-augsuppjns2014","series-title":"Stroke","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1161\/STR.0b013e3181ec611b","article-title":"Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"41","author":"Morgenstern","year":"2010"},{"issue":"2","key":"b58-augsuppjns2014","series-title":"Stroke","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1161\/STROKEAHA.109.561795","article-title":"Effects of early intensive blood pressure-lowering treatment on the growth of hematoma and perihematomal edema in acute intracerebral hemorrhage: the Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT)","volume":"41","author":"Anderson","year":"2010"},{"issue":"8","key":"b59-augsuppjns2014","series-title":"Stroke","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1161\/STROKEAHA.112.651422","article-title":"Earlier blood pressure-lowering and greater attenuation of hematoma growth in acute intracerebral hemorrhage: INTERACT pilot phase","volume":"43","author":"Arima","year":"2012"},{"key":"b60-augsuppjns2014","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1056\/NEJMoa1214609","article-title":"Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage","volume":"368","author":"Anderson","year":"2013"},{"key":"b61-augsuppjns2014","series-title":"Hypertension","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1161\/HYPERTENSIONAHA.110.154328","article-title":"Lower treatment blood pressure is associated with greatest reduction in hematoma growth after acute intracerebral hemorrhage","volume":"56","author":"Arima","year":"2010"},{"key":"b62-augsuppjns2014","series-title":"Curr Opin Crit Care","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/MCC.0b013e3283513279","article-title":"Blood pressure control for acute ischemic and hemorrhagic stroke","volume":"18","author":"Grise","year":"2012"},{"key":"b63-augsuppjns2014","series-title":"Arch Neurol","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1001\/archneurol.2010.61","article-title":"Effect of systolic blood pressure reduction on hematoma expansion, perihematomal edema, and 3-month outcome among patients with intracerebral hemorrhage: results from the antihypertensive treatment of acute cerebral hemorrhage study","volume":"67","author":"Qureshi","year":"2010"},{"key":"b64-augsuppjns2014","series-title":"Rinsho Ketsueki","first-page":"377","article-title":"[Study on guidelines for the treatment of DIC]","volume":"48","author":"Wada","year":"2007"},{"key":"b65-augsuppjns2014","series-title":"Thromb Haemost","first-page":"111","article-title":"Should oral anticoagulants be restarted after warfarin-associated intracerebral haemorrhage in patients with atrial fibrillation?","author":"Paciaroni","year":"2014"},{"key":"b66-augsuppjns2014","series-title":"Nat Rev Neurol","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/nrneurol.2011.6","article-title":"Brain hemorrhage: restarting anticoagulation after intracranial hemorrhage","volume":"7","author":"Marsh","year":"2011"},{"key":"b67-augsuppjns2014","series-title":"Stroke","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.1161\/STROKEAHA.110.593087","article-title":"Optimal timing of resumption of warfarin after intracranial hemorrhage","volume":"41","author":"Majeed","year":"2010"},{"key":"b68-augsuppjns2014","series-title":"Anesthesiology","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1097\/ALN.0b013e318297c18a","article-title":"Perioperative management of coagulation in nontraumatic intracerebral hemorrhage","volume":"119","author":"Degos","year":"2013"},{"key":"b69-augsuppjns2014","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.3171\/2013.1.JNS121849","article-title":"Management of intracranial hemorrhage in patients with left ventricular assist devices","volume":"118","author":"Wilson","year":"2013"},{"key":"b70-augsuppjns2014","series-title":"Stroke","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.1161\/STR.0b013e318266722a","article-title":"Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"43","author":"Furie","year":"2012"},{"key":"b71-augsuppjns2014","series-title":"Chest","doi-asserted-by":"publisher","first-page":"e152S","DOI":"10.1378\/chest.11-2295","article-title":"Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Holbrook","year":"2012"},{"key":"b72-augsuppjns2014","series-title":"Lancet","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0140-6736(05)70233-6","article-title":"Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial","volume":"365","author":"Mendelow","year":"2005"},{"key":"b73-augsuppjns2014","series-title":"Acta Neurochir Suppl","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/978-3-211-09469-3_30","article-title":"Preliminary findings of the minimally-invasive surgery plus rtPA for intracerebral hemorrhage evacuation (MISTIE) clinical trial","volume":"105","author":"Morgan","year":"2008"},{"key":"b74-augsuppjns2014","series-title":"Acta Neurochir Suppl","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/3-211-30714-1_16","article-title":"Intraventricular hemorrhage and hydrocephalus after spontaneous intracerebral hemorrhage: results from the STICH trial","volume":"96","author":"Bhattathiri","year":"2006"},{"issue":"5","key":"b75-augsuppjns2014","series-title":"Surg Neurol","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.surneu.2006.05.054","article-title":"Early surgical treatment vs conservative management for spontaneous supratentorial intracerebral hematomas: A prospective randomized study","volume":"66","author":"Pantazis","year":"2006"},{"issue":"6","key":"b76-augsuppjns2014","series-title":"Stroke","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1161\/STROKEAHA.111.640284","article-title":"Individual patient data subgroup meta-analysis of surgery for spontaneous supratentorial intracerebral hemorrhage","volume":"43","author":"Gregson","year":"2012"},{"key":"b77-augsuppjns2014","series-title":"Lancet","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0140-6736(13)60986-1","article-title":"Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematomas (STICH II): a randomised trial","volume":"382","author":"Mendelow","year":"2013"},{"issue":"4","key":"b78-augsuppjns2014","series-title":"Cochrane Database Syst Rev","first-page":"CD000200","article-title":"Surgery for primary supratentorial intracerebral haemorrhage","volume":"8","author":"Prasad","year":"2008"},{"key":"b79-augsuppjns2014","series-title":"Neurocrit Care","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1385\/NCC:3:3:237","article-title":"Frameless stereotactic aspiration and thrombolysis of spontaneous intracerebral hemorrhage","volume":"3","author":"Barrett","year":"2005"},{"key":"b80-augsuppjns2014","series-title":"Stroke","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1161\/STROKEAHA.110.610949","article-title":"Low-dose recombinant tissue-type plasminogen activator enhances clot resolution in brain hemorrhage: the intraventricular hemorrhage thrombolysis trial","volume":"42","author":"Naff","year":"2011"},{"key":"b81-augsuppjns2014","series-title":"Neurocrit Care","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1385\/NCC:2:3:274","article-title":"Frameless stereotactic aspiration and thrombolysis of deep intracerebral hemorrhage is associated with reduction of hemorrhage volume and neurological improvement","volume":"2","author":"Vespa","year":"2005"},{"key":"b82-augsuppjns2014","series-title":"Stroke.","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1161\/STROKEAHA.112.667535","article-title":"Minimally invasive surgery for spontaneous supratentorial intracerebral hemorrhage: a meta-analysis of randomized controlled trials","volume":"43","author":"Zhou","year":"2012"},{"issue":"4","key":"b83-augsuppjns2014","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"530","DOI":"10.3171\/jns.1989.70.4.0530","article-title":"Endoscopic surgery versus medical treatment for spontaneous intracerebral hematoma: a randomized study","volume":"70","author":"Auer","year":"1989"},{"key":"b84-augsuppjns2014","series-title":"Stroke","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1161\/01.STR.0000063367.52044.40","article-title":"Stereotactic treatment of intracerebral hematoma by means of a plasminogen activator: a multicenter randomized controlled trial (SICHPA)","volume":"34","author":"Teernstra","year":"2003"},{"issue":"3","key":"b85-augsuppjns2014","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"592","DOI":"10.3171\/2011.5.JNS10505","article-title":"Minimally invasive evacuation of spontaneous intracerebral hemorrhage using sonothrombolysis","volume":"115","author":"Newell","year":"2011"},{"key":"b86-augsuppjns2014","series-title":"Surg Neurol","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.surneu.2005.09.032","article-title":"Endoscopic surgery for spontaneous basal ganglia hemorrhage: comparing endoscopic surgery, stereotactic aspiration, and craniotomy in noncomatose patients","volume":"65","author":"Cho","year":"2006"},{"key":"b87-augsuppjns2014","series-title":"Cerebrovasc Dis","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1159\/000069489","article-title":"Subacute stereotactic aspiration of haematomas within the basal ganglia reduces occurrence of complications in the course of haemorrhagic stroke in non-comatose patients","volume":"15","author":"Marquardt","year":"2003"},{"key":"b88-augsuppjns2014","article-title":"Misti Trial: 365-day Results Demonstrate Improved Outcomes and Cost Benefit","author":"Hanley","year":"2013"},{"issue":"3","key":"b89-augsuppjns2014","series-title":"Stroke","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1161\/STROKEAHA.111.000411","article-title":"Minimally invasive surgery plus recombinant tissue-type plasminogen activator for intracerebral hemorrhage evacuation decreases perihematomal edema","volume":"44","author":"Mould","year":"2013"},{"key":"b90-augsuppjns2014","series-title":"Crit Care Med","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1097\/00003246-200103000-00031","article-title":"Admission to a neurologic\/neurosurgical intensive care unit is associated with reduced mortality rate after intracerebral hemorrhage","volume":"29","author":"Diringer","year":"2001"},{"issue":"Suppl 1","key":"b91-augsuppjns2014","series-title":"Neurocrit Care","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1007\/s12028-012-9757-2","article-title":"Emergency neurological life support: intracerebral hemorrhage","volume":"17","author":"Andrews","year":"2012"},{"issue":"6","key":"b92-augsuppjns2014","series-title":"Thromb Haemost","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1160\/TH10-05-0328","article-title":"Clinical laborato-laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay","volume":"104","author":"Barrett","year":"2010"},{"key":"b93-augsuppjns2014","series-title":"(coagulation factor ix human) kit. Package insert","author":"Bebulin"},{"issue":"2","key":"b94-augsuppjns2014","series-title":"J Thromb Thrombolysis","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s11239-011-0591-8","article-title":"Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban\u2014an oral, direct and selective factor Xa inhibitor","volume":"32","author":"Becker","year":"2011"},{"issue":"21","key":"b95-augsuppjns2014","series-title":"Eur Heart J","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association","volume":"33","author":"Camm","year":"2012"},{"key":"b96-augsuppjns2014","doi-asserted-by":"publisher","author":"ClinicalTrials.gov","DOI":"10.1016\/S0895-7967(02)70025-2"},{"key":"b97-augsuppjns2014","doi-asserted-by":"publisher","author":"CSL Behring","DOI":"10.1016\/j.ahj.2004.11.015"},{"issue":"4","key":"b98-augsuppjns2014","series-title":"Semin Vasc Surg","doi-asserted-by":"publisher","first-page":"256","DOI":"10.2165\/0003088-200948010-00001","article-title":"Anticoagulants: to bleed or not to bleed, that is the question","volume":"15","author":"Da Silva","year":"2002"},{"issue":"4","key":"b99-augsuppjns2014","series-title":"Am Heart J","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.ahj.2005.04.017","article-title":"Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study","volume":"149","author":"DiMarco","year":"2005"},{"issue":"1","key":"b100-augsuppjns2014","series-title":"Clin Pharmacokinet","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.amjmed.2005.02.022","article-title":"Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development","volume":"48","author":"Eriksson","year":"2009"},{"issue":"3","key":"b101-augsuppjns2014","series-title":"Am Heart J","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1097\/FTD.0b013e3181f2f264","article-title":"Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF)","volume":"151","author":"Gage","year":"2006"},{"issue":"6","key":"b102-augsuppjns2014","series-title":"Am J Med","first-page":"612","article-title":"Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall","volume":"118","author":"Gage","year":"2005"},{"issue":"6","key":"b103-augsuppjns2014","series-title":"Ther Drug Monit","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1378\/chest.10-0134","article-title":"Assays for measuring rivaroxaban: their suitability and limitations","volume":"32","author":"Lindhoff-Last","year":"2010"},{"key":"b104-augsuppjns2014","author":"Orlando Regional Medical Center"},{"issue":"5","key":"b105-augsuppjns2014","series-title":"Chest","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1182\/blood-2011-10-378950","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010"},{"key":"b106-augsuppjns2014","series-title":"Profilnine SD (factor ix complex). Package insert","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-5-200909010-00003"},{"issue":"13","key":"b107-augsuppjns2014","series-title":"Blood","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1093\/eurheartj\/ehr052","article-title":"How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch","volume":"119","author":"Schulman","year":"2012"},{"issue":"5","key":"b108-augsuppjns2014","series-title":"Ann Intern Med","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1160\/TH09-11-0758","article-title":"The net clinical benefit of warfarin anticoagulation in atrial fibrillation","volume":"151","author":"Singer","year":"2009"},{"issue":"16","key":"b109-augsuppjns2014","series-title":"Eur Heart J","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1161\/CIRCULATIONAHA.112.123224","article-title":"Novel oral anticoagulants: focus on stroke prevention and treatment of venous thromboembolism","volume":"32","author":"Steffel","year":"2011"},{"issue":"6","key":"b110-augsuppjns2014","series-title":"Thromb Haemost","first-page":"1116","article-title":"Dabigatran etexilate\u2014a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity","volume":"103","author":"van Ryn","year":"2010"},{"issue":"20","key":"b111-augsuppjns2014","series-title":"Circulation","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1093\/brain\/aws349","article-title":"Periprocedural management and approach to bleeding in patients taking dabigatran","volume":"126","author":"Weitz","year":"2012"}],"container-title":["Journal of Neurosurgery"],"original-title":[],"link":[{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/121\/Suppl\/article-p1.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/121\/Suppl\/article-p1.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/121\/Suppl\/article-p1.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T00:14:39Z","timestamp":1658708079000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/121\/Suppl\/article-p1.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":111,"journal-issue":{"issue":"Suppl"},"URL":"https:\/\/doi.org\/10.3171\/2014.8.paradigm","relation":{},"ISSN":["0022-3085","1933-0693"],"issn-type":[{"value":"0022-3085","type":"print"},{"value":"1933-0693","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8]]}}}